PHL P 5A DERIVATIVES HAVING REDUCED ALLERGENEITY AND RETAINED T-CELL REACTIVITY

Abstract

The present invention relates to the preparation and use of variants of the group 5 allergen of the Pooideae which are characterised by reduced IgE reactivity compared with the known wild-type allergens and at the same time by substantially retained reactivity with T lymphocytes. These hypoallergenic allergen variants can be employed for the specific immunotherapy (hyposensitisation) of patients having grass pollen allergy or for the preventative immunotherapy of grass pollen allergies.

Description

[0001] The present invention relates to the preparation and use of variants of the group 5 allergen of the Pooideae which are characterised by reduced IgE reactivity compared with the known wild-type allergens and at the same time by substantially retained reactivity with T lymphocytes. These hypoallergenic allergen variants can be employed for the specific immunotherapy (hyposensitisation) of patients having grass pollen allergy or for the preventative immunotherapy of grass pollen allergies. A preferred embodiment of the invention relates to variants of the major allergen Phl p 5a from the pollen of timothy grass (Phleum pratense).

BACKGROUND OF THE INVENTION

[0002] Type 1 allergies are of importance worldwide. Up to 20% of the population in industrialised countries suffer from complaints such as allergic rhinitis, conjunctivitis or bronchial asthma. These allergies are caused by allergens present in the air (aeroallergens) which are liberated from sources of various origin, such as plant pollen, mites, cats or dogs. Up to 40% of these type 1 allergy sufferers in turn exhibit specific IgE reactivity with grass pollen allergens (Freidhoff et al., 1986, J. Allergy Clin, Immunol. 78, 1190-2002).

[0003] The substances which trigger type 1 allergy are proteins, glycoproteins or polypeptides. After uptake via the mucous membranes, these allergens react with the IgE molecules bonded to the surface of mast cells in sensitised individuals. If two IgE molecules are crosslinked to one another by an allergen, this results in the release of mediators (for example histamine, prostaglandins) and cytokines by the effector cell and thus in the corresponding clinical symptoms.

[0004] A distinction is made between major and minor allergens depending on the relative frequency with which the individual allergen molecules react with the IgE antibodies of allergy sufferers.

[0005] In the case of timothy grass (Phleum pratense), Phi p 1 (Petersen et al., 1993, J. Allergy Clin. Immunol. 92: 789-796), Phl p 5 (Matthiesen and Lowenstein, 1991, Clin, Exp. Allergy 21: 297-307; Petersen at al, 1992, Int. Arch. Allergy Immunol. 98: 105-109), Phi p 6 (Petersen at al., 1995, Int. Arch, Allergy Immunol. 108, 49-54). PN p 2/3 (Dolecek et al., 1993, FESS 335 (3), 299-304), Phl p 4 (Haavik et al., 1985, Int. Arch. Allergy Appl, Immunot 78: 260-268; Valenta et al., 1992, Int. Arch. Allergy Immunol. 97: 287-294, Fischer et al., 1996, J. Allergy Clin, Immunol. 98: 189-198) and Phi p 13 (Suck et al., 2000, Clin. Exp. Allergy 30: 324-332; Suck et al., 2000, Clin. Exp. Allergy 30: 1395-1402) have hitherto been identified as major allergens.

[0006] The dominant major allergens of timothy grass (Phleum pratense) are Phl p 1 and Phl p 5, with Phl p 5 occurring in two forms 5a and 5b which differ in respect of theft molecular weight and are encoded by independent genes. The deduced amino acid sequences both of Phl p 5a and also of Phl p 5b have been determined by means of the recombinant DNA technique, Phl p 5a is a protein of about 32 kDa and reacts with the IgE antibodies of 85-90% of grass pollen allergy sufferers. Phl p 5a exists in a series of homologous variants which differ from one another through point mutations and probably correspond to different allelic forms. The pollen of related grass species, such as, for example, Lolium perenne, Poa pratensis inter alia, contains allergens which are homologous with that of Phl p 5a and together are known as group 5 allergens. The high structural homology of these group 5 allergens of grass species causes correspondingly high cross reactivity of the molecules with the IgE antibodies of grass pollen allergy sufferers.

[0007] A classical approach to effective therapeutic treatment of allergies is specific immunotherapy or hyposensitisation (Fiebig, 1995, Allergo J. 4 (6): 336-339, Bousquet et al., 1998, J. Allergy Clin. Immunol, 102 (4): 558-562). In this method, the patient is injected subcutaneously with natural allergen extracts in increasing doses. However, there is a risk in this method of allergic reactions or even anaphylactic shock. In order to minimise these risks, innovative preparations in the form of allergoids are employed. These are chemically modified allergen extracts which have significantly reduced IgE reactivity, but identical T-cell reactivity compared with the untreated extract (Fiebig, 1995, Allergo J. 4 (7): 377-382).

[0008] Even more substantial therapy optimisation would be possible with allergens prepared by recombinant methods. Defined cocktails of high-purity allergens prepared by recombinant methods, optionally matched to the individual sensitisation patterns of the patients, could replace extracts from natural allergen sources since these, in addition to the various allergens, contain a relatively large number of immunogenic, but non-allergenic secondary proteins. Realistic perspectives which may result in reliable hyposensitisation with recombinant expression products are offered by specifically mutated recombinant allergens in which IgE epitopes are specifically deleted without impairing the T-cell epitopes which are essential for therapy (Schramm et al., 1999, J. Immunol. 162: 2406-2414).

[0009] A further possibility for therapeutic influencing of the disturbed T helper cell equilibrium in allergy sufferers is treatment with expressible DNA which encodes for the relevant allergens (immunotherapeutic DNA vaccination). Initial experimental evidence of allergen-specific influencing of the immune response by a DNA vaccine of this type has been furnished in rodents by injection of allergen-encoding DNA (Hsu et al., 1996, Nature Medicine 2 (5): 540-544).

[0010] The object on which the present invention is based consisted in the provision of novel variants of the group 5 allergens of the Pooideae at the protein and DNA level which are distinguished by reduced IgE activity at the same time as substantial retention of the T-cell reactivity and are therefore suitable for specific immunotherapy and immunotherapeutic DNA vaccination.

BRIEF DESCRIPTION OF THE DRAWINGS

[0011] FIG. 1 shows sequence alignment of relevant regions of Phl p 5a-homologous cDNA sequences of Pooideae species: Lolium perenne (Lol p), Poa pratensis (Poa p) Triticum aestivum (Tri a) and Hordeum vulgare (Hor v). The numbering represents nucleotide positions of the DNA insertions.

[0012] FIG. 2A and FIG. 2B together show sequence alignment of Phl p 5a-homologous amino acid sequences (relevant sequence regions, deduced from DNA sequences) of Pooideae species: Lolium perenne (Lol p), Poa pratensis (Poa p) Triticum aestivum (Tri a) and Hordeum vulgare (Hor v). The numbering represents nucleotide positions of the DNA insertions.

[0013] FIG. 3 shows SDS-PAGE of purified deletion mutants in the form of histidine fusion proteins. Lanes represent the following: (1) marker; (2) rPhl p 5a wt (His); (3) Phl p 5a DM-.DELTA.94-113 (His); (4) Phl p 5a DM-.DELTA.94-113, 175-198 (His); (5) Phl p 5a DM-.DELTA.75-198 (His); (6) Marker

[0014] FIG. 4 shows SDS-PAGE of the purified non-fusion proteins Phl p 5a DM-D94-113, 175-198 and rPhl p 5a wt (top) and identity test with .alpha.Phi p 5 antibodies (bottom). Note: .alpha.Phl p 5 mAb Apha-1D11 binds region 175-198 (only rPhl p 5a wt is positive) and .alpha.Phl p 5a mAb Apha-3B2 binds a joint epitope of the two Phl p 5a molecules (both proteins positive). Abbreviation: mAb means monoclonal antibody.

[0015] FIG. 5 shows analytical SEC of deletion mutant Phl p 5a DM-.DELTA.94-113, 175-198 and of recombinant wild type Phl p 5a (purified non-fusion proteins)

[0016] FIG. 6 shows results on non-denaturing isoelectric focusing of deletion mutant Phl p 5a DM-.DELTA.94-113, 175-198 and of recombinant wild type Phl p 5a (purified non-fusion proteins). Lanes represent the following: (1) IEF marker; (2) rPhl p 5a wt; (3) Phl p 5a DM-.DELTA.94-113, 175-198

[0017] FIG. 7 shows results on strip test for checking the IgE binding ability of Phl p 5a deletion mutants (non-denaturing). Abbreviation: P is sera of clinically defined grass pollen allergy sufferers.

[0018] FIG. 8 shows determination of the reduced IgE reactivity of Phl p 5a deletion mutants by means of the EAST inhibition test with two representative single sera (a) and (b) and a serum pool (c). Abbreviation: P is sera of clinically defined grass pollen allergy sufferers.

[0019] FIG. 9 shows determination of the hypoallergeneity of Phl p 5a deletion mutant Phl p 5a DM-.DELTA.94-113, 175-198 by means of the basophil activation test with basophils of six different grass pollen allergy sufferers (P).

DETAILED DESCRIPTION OF THE INVENTION

Mutagenesis and Cloning of cDNA Sequences

[0020] The starting point for the--particularly preferred in accordance with the invention--hypoallergenic Phl p 5a variants is the cDNA of an isoform of wild-type Phl p 5a which has been isolated with the aid of specific primers by polymerase chain reaction (PCR) from the total cDNA of pollen of timothy grass (Phleum pratense) (NCBI (National Center for Biotechnology Information, Bethesda, USA) GenBank number AJ555152) (SEQ ID NO 1). The amino acid sequence as per SEQ ID NO 2 has been deduced from the cDNA sequence. Phl p 5a, which consists of 284 amino acids, was expressed cytosolically as soluble protein in E. coli and subsequently purified. This recombinant wild-type form of Phl p 5a (rPhl p 5a wt) reacts with monoclonal anti-Phl p 5 antibodies and with IgE antibodies of grass pollen allergy sufferers which have reactivity with natural purified Phi p 5a (nPhl p 5a).

[0021] Starting from the described cDNA of rPhl p 5a wt, a series of different deletion variants (deletion mutants) was prepared by restriction/ligation methods and PCR and ligated into the expression vector pProExHTa (invitrogen, Carlsbad, USA). Sections with a length of 6 to 72 by distributed over the entire sequence of the cDNA molecule were deleted, causing induction of corresponding deletions in the polypeptide chains of the proteins expressed in E. coli.

[0022] The deletion variants of Phl p 5a were investigated by immunoblot for their binding ability to IgE antibodies of a representative serum pool of grass pollen allergy sufferers.

[0023] In this method, surprisingly, two deletion variants of Phl p 5a (Phl p 5a DM-.DELTA.94-113, deletion of amino acids 94-113 and Phl p 5a DM-.DELTA.175-198, deletion of amino acids 175-198 of rPhl p 5a wt) were found, which have reduced binding of IgE antibodies (representative serum pool).

[0024] These two Phl p 5a deletions served as starting point for the construction of a double deletion mutant containing both effective deletions (Phl p 5a DM -.DELTA.94-113, 175-198).

[0025] The construction of Phl p 5a DM-.DELTA.94-113, Phl p 5a DM-.DELTA.175-198 and Phl p 5a DM-.DELTA.94-113, 175-198 by genetic engineering methods and the biochemical and immunological characterisation thereof are described below.

[0026] For the construction of deletion variant Phl p 5a DM-.DELTA.94-113 (SEQ ID NO 3, cDNA sequence (795 bp), and SEQ ID NO 4, amino acid sequence (264 aa)), firstly two fragments were prepared starting from the cDNA of rPhl p 5a wt. Fragment "F1-93", encoding for amino acids 1-93 of rPhl p 5a wt, was prepared by PCR with the aid of primers 1 and 5, and fragment "F114-284" was prepared with the aid of primers 4 and 6 (primer sequences see Table 1). Fragments "F1-93" and "F114-284" were employed as matrix in a further PCR using primers 1 and 4, which resulted in amplification of the complete cDNA encoding for deletion variant Phl p 5a DM-.DELTA.94-113. The basis of the connection of fragments "F1-93" and "F114-284" by PCR was a sequence region common to both fragments. This sequence region was formed by amplification of fragment "F114-284" by PCR by means of a particular sense oligonucleotide which contained an additional DNA sequence encoding for amino acids 88-93 in the 5' region (Table 1).

[0027] The cDNA sequence encoding for deletion variant Phi p 5a DM-.DELTA.175-198 (SEQ ID NO 5, cDNA sequence (783 bp), and SEQ ID NO 6, amino acid sequence (260 aa)) was generated by restriction and subsequent ligation of two separately prepared cDNA fragments. The 5'-terminal fragment "F1-174" was prepared by PCR with the aid of primers 1 and 2 and the 3'-terminal fragment "F199-284" with the aid of primers 3 and 4. The cDNA fragments were digested with the restriction enzyme Spel and subsequently ligated (see Table 1). The ligation product was amplified by PCR using primers 1 and 4.

[0028] The cDNA of deletion variant Phl p 5a DM-A94-113, 175-198 (SEQ ID NO 7, cDNA sequence (723 bp), and SEQ ID NO 8, amino acid sequence (240 aa)) was likewise prepared from two cDNA fragments. The b'-terminal fragment was generated using primers 1 and 5 and with rPhl p 5a wt-cDNA as matrix, and the 3'-terminal fragment was generated using primers 4 and 6 with Phi p 5a DM-.DELTA.175-198-cDNA as matrix. By means of the common sequence region corresponding to amino acids 88-93 of the rPhl p 5a wt protein, the fragments were connected by a third PCR using primers 1 and 4, and the product was amplified.

[0029] The cDNAs encoding for the modified allergens were ligated into the expression vector pProExHT (Invitrogen, Carlsbad, USA) via the Ehel and HindIII restriction sites and subsequently sequenced in full.

[0030] The immunological cross reactivity of the group 5 allergens of the Pooideae, such as, for example, Poa pratensis and Lolium peronne, is based on a very similar amino acid sequence. It can be taken as certain that the corresponding genes go back to a common progenitor gene. Homologous sequence regions in the group 5 allergens of the Pooideae exist both for the sequences of deletions .DELTA.94-113 and .DELTA.175-198 of the Phl p 5a wt protein sequence (reference: GenBank AJ555152) and also for the flanking sequence regions thereof. The high homology of the sequence regions in question can be demonstrated both at the DNA level and also at the amino acid sequence level (FIG. 1 and FIG. 2).

TABLE-US-00001 TABLE 1 List of the PCR primers employed for the preparation of deletion variants SEQ Primer ID NO Direction Sequence (5'.fwdarw.3') 1 9 sense gcc gat cta ggc tac ggc ccg gcc 2 10 antisense aac ata act agt ggc agc gac ctt gaa ggc ggc gtc 3 11 sense atc ta act agt acg ggc ggc gcc tac gaga 4 12 antisense aac ata aag ctt tca gac ttt gta gcc acc agt 5 13 antisense gga gct gga ttc ggc ggc gcc ctt ggg 6 14 sense gcc gcc gaa tcc agc tcc ggc gcg acg cct gag gcc aag tac gac

[0031] The Spel restriction sites are indicated by underlining

Expression and Purification of Recombinant Phl p 5a Molecules

[0032] The recombinant proteins were expressed as histidine fusion proteins with integrated protease cleavage site (expression vector pProExHT; Invitrogen, Carlsbad, USA) for optional removal of the histidine fusion component (His) in Escherichia coil (strain JM109). rPhl p5a wt and the deletion mutants were firstly purified by specific binding of the N-terminal histidine residues to an Ni2+ chelate matrix (immobilised metal ion affinity chromatography, IMAC) and subsequently by preparative gel filtration (size exclusion chromatography, SEC).

[0033] The purity of the eluted proteins was monitored by SDS-PAGE and analytical SEC. The results showed that rPhl p 5a wt (His), Phl p 5a DM-.DELTA.94-113 (His); Phl p 5a DM-.DELTA.175-198 (His) and Phl p 5a DM-.DELTA.94-113, 175-198 (His) could be prepared with high purity and in monomeric form (FIG. 3). The identity of the proteins was demonstrated by Phl p 5a-specific monoclonal antibodies.

[0034] The checking of the IgE reactivity by means of IgE binding techniques (immunoblotting, strip test, EAST inhibition test and basophil activation test) and the investigation of the T-cell reactivity was in addition carried out with test substances without a histidine fusion component.

[0035] To this end, the deletion variants was prepared in parallel to the comparative protein rPhl p 5a-wt firstly as fusion proteins. However, the histidine fusion component was subsequently cleaved off enzymatically (TEV protease, Invitrogen, Carlsbad, USA), leaving only a glycine as residue of the protease cleavage sequence on the N terminal of the target protein. Both the cleaved-off histidine component and also the protease used for the cleavage were separated off completely by IMAC. After preparative SEC, the purity and conformation of the eluted proteins was checked by SDS-PAGE and analytical SEC, as shown in FIGS. 4 and 5 for rPhl p 5a kkrt and the mutant Phl p 5a DM-.DELTA.94-113, 175-198 respectively. All proteins were prepared in pure and monomeric form. An investigation by non-denaturing isoelectric focusing (IEF) of the non-fusion proteins always showed high homogeneity with respect to the surface charge (see FIG. 6, illustrative for Phl p 5a DM-.DELTA.94-113, 175-198). The identity of the recombinant proteins was demonstrated by the monoclonal anti-Phl p 5 antibodies (Ailergopharma, Reinbek, Germany) Apha-1D11 or Apha-3B2 (see FIG. 4, illustrative for Phl p 5a DM-.DELTA.94-113, 175-198) and N-terminal sequencing.

Determination of Reduced IgE Binding of the Phl p 5a Deletion Variants

[0036] A simple test method for determination of the IgE reactivity of allergenic molecules is investigation of the binding of specific IgE from the sera from allergy sufferers to membrane-bound test proteins by the strip test. For this purpose, the test substances are bound in the same concentration and amount alongside one another to a strip of nitrocellulose membrane under non-denaturing conditions. A series of such membrane strips can be incubated in parallel with various sera from allergy sufferers. After a washing step, the specifically bound IgE antibodies are rendered visible on the membrane by a colour reaction promoted by an anti-hIgE/alkaline phosphatase conjugate.

[0037] The IgE reactivity of the recombinant proteins Phl p 5a wt (His), Phl p 5a DM.DELTA.94-113 (His), Phl p 5a DM-A175-198 (His) and Phl p 5a DM-.DELTA.94-113, 175-198 (His) was investigated comparatively in the strip test using 43 individual sera from grass pollen allergy sufferers (FIG. 7).

[0038] All 43 sera from allergy sufferers contained Phl p 5a-specific IgE antibodies which reacted strongly with the natural Phl p 5a (nPhl p 5a, not shown here) and the recombinant equivalent rPhl p 5a wt (His). Surprisingly, it became clear that the Phl p 5a-specific IgE antibodies of all 43 patient sera did not bind at all to deletion variant Phl p 5a DM-.DELTA.94-113, 175-198 (His) or only did so to a very greatly reduced extent. The reduced IgE binding is attributable both to the deletion .DELTA.94-113 and also to the deletion .DELTA.175-198, Deletion variant Phl p 5a DM-.DELTA.175-198 (His) shows a clearly recognisably reduced IgE binding capacity in this test in 35 of 43 sera from allergy sufferers. In some tests, the influence of the deletion of amino acids 175-198 was so great that IgE binding was virtually completely prevented (Ex.: P3, P20, P28)

[0039] The influence of deletion .DELTA.94-113 on the IgE binding reactivity is less pronounced, but likewise clearly visible. Deletion variant Phl p 5a DM-.DELTA.94-113 (His) was bound significantly more weakly by IgE of 19 of the 43 individual sera from allergy sufferers than the reference rPhl p 5a wt (His) (Ex.: P31, P37, P42). However, the reduction in the IgE binding was less drastically pronounced in many individual tests than the reduction caused by .DELTA.75-198.

[0040] It is thus clear that both deletions contribute to the reduction in the total IgE binding reactivity of the deletion mutant Phl p 5a DM-.DELTA.94-113, 175-198 (His).

[0041] In contrast to the strip test, the EAST inhibition test (enzyme allergosorbent test) allows the investigation of allergen/IgE interactions in solution, enabling interfering masking of epitopes of the test substance by immobilisation on the membrane to be fundamentally excluded. The EAST inhibition test is carried out as follows. Microtitre plates are coated with allergens, here natural Phl p 5 (nPhl p 5a/b, mixture of Phl p 5a and Phl p 5b). After removal of the unbound allergen molecules by washing, the plate is blocked with bovine serum albumin in order to prevent later nonspecific binding. IgE antibodies of allergy sufferers, as representative pool of individual sera (serum pool) or as single serum, is incubated in suitable dilution with the allergen-coated rnicrotitre plates. The amount of allergen-bound IgE antibodies is quantified photometrically via an enzyme coupled to a second antibody (anti-hIgE/alkaline phosphatase conjugate) through conversion of a substrate into a coloured end product. The binding of the IgE antibodies is inhibited substance-specifically by a soluble allergen or the substance to be tested (recombinant modified allergen) depending on the concentration. Immunochemically identical substances show identical inhibition curves.

[0042] The reference molecules used in this work were nPhl p 5, rPhl p 5a wt, and the histidine fusion protein rPhl p 5a wt (His). Besides other molecules, the IgE binding of the histidine fusion proteins Phl p 5a DM-.DELTA.94-113 (His), Phl p 5a DM-.DELTA.175-198 (His) and Phl p 5a DM-.DELTA.94-113, 175-198 (His) and that of the non-fusion protein Phi p 5a DM-.DELTA.94-113, 175-198 was investigated by comparison with these references.

[0043] FIGS. 8 a-c show representatively the specific inhibition curves of test substances raised with two individual sera and a serum pool of grass pollen allergy sufferers. nPhl p 5a/b showed the greatest inhibitory effect in all tests (about 80-95% inhibitory effect at a concentration of 10 .mu.g/ml). The inhibitory effect of rPhl p 5a was significantly lower with a maximum inhibition of 70-80%. This effect is caused by the composition of nPhl p 5a/b, which also contains the isoform Phl p 5b in addition to the isoform Phl p 5a. The specific IgE antibodies against Phl p 5b cannot be inhibited by rPhl p 5a wt.

[0044] The histidine fusion component showed no effect on IgE binding. This is clear in all tests through the identical inhibition curves of rPhl p 5a wt (His) and rPhl p 5a wt. This demonstrates the validity of tests with histidine fusion proteins.

[0045] In general, two groups of patient sera were distinguished with respect to qualitative IgE binding.

[0046] The first group is represented by individual serum P15 (FIG. 8 a). These sera from allergy sufferers contained IgE antibodies whose binding to Phi p 5a was reduced by both deletions, .DELTA.94-113 and .DELTA.175-198. Deletion mutant Phl p 5a DM-.DELTA.94-113 (His) showed only a maximum inhibitory effect of about 50% here, and the deletion mutant Phl p 5a DM-175-198 (His) showed an inhibitory effect of only 20-30%.

[0047] The double deletion mutant Phl p 5a DM-.DELTA.94-113, 175-198 (His) was only able to inhibit the binding of IgE antibodies by 0-10% at the highest concentration employed. The use of the non-fusion protein Phl p 5a DM-.DELTA.94-113, 175-198 confirmed this result (0-10% maximum IgE inhibition).

[0048] The second group of sera from allergy sufferers, represented by individual serum P44 (FIG. 8 b), differed from the first group through the fact that the IgE antibodies present in the sera reacted equally well with Phl p 5a DM-.DELTA.94-113 (His) as with the reference rPhl p 5a wt (His) (70-80% maximum inhibition), whereas no or non-detectable amounts of IgE antibodies reacted with Phl p 5a DM-.DELTA.175-198 (His) (0-10% maximum inhibition).

[0049] The double deletion mutant Phl p 5a DM-A94-113, 175-198 likewise showed a greatly reduced inhibitory effect (0-10%) with this group of sera from allergy sufferers, which was shown both for the fusion protein and also for the fusion component-free protein.

[0050] The sera of these allergy sufferers apparently contained IgE antibodies directed principally against epitopes of the C-terminal part of the molecule.

[0051] The measurement data of the IgE binding reactivity of IgE antibodies of a serum pool of 20 allergy sufferers underline the importance of the deletions .DELTA.94-113 and .DELTA.175-198 for the reduction in the IgE binding of Phl p 5a (FIG. 8 c). Both individual deletion mutants, Phl p 5a DM-.DELTA.94-113 (His) and Phl p 5a DM-.DELTA.175-198 (His) show a lower maximum inhibitory effect, of 40-50% and about 30% respectively, than rPhl p 5a wt (about 70%). The double deletion mutant Phl p 5a DM-.DELTA.94-113, 175-198 was only bound very weakly by the IgE antibodies of the serum pool (10-15% maximum inhibition), which, in agreement with the test of 43 allergy sufferers in the strip test, indicates greatly reduced IgE binding reactivity of this Phl p 5a variant in very many, if not all, grass pollen allergy sufferers.

Determination of the Hypoallergeneity of the Deletion Mutants by Basophil Activation Test

[0052] By means of a basophil activation test, the effects of reduced IgE binding ability of the deletion mutants on the functional effect in the crosslinking of membrane-bound IgE of the effector cells and activation thereof were investigated. The functional reduction in allergeneity was thus measured in a sensitive in-vitro test.

[0053] For the basophil activation test, heparinised full blood from grass pollen allergy sufferers is incubated with various concentrations of the test substances. Allergenic substances are able to bind specific IgE antibodies, which are associated with the high-affinity IgE receptors of the basophilic granulocytes. Crosslinking of the IgE/receptor complexes initiated by the allergen molecules results in signal transduction, which results in degranulation of the effector cells and thus initiation of the allergic reactions in vivo.

[0054] In vitro, allergen-induced activation of basophilic immunocytes can be determined by quantification of the expression of a surface protein (CD203c) coupled to signal transduction of the IgE receptor crosslinking (Kahlert et al., Clinical Immunology and Allergy in Medicine Proceedings of the EAACI 2002 (2003) Naples, Italy 739-744). The number of expressed surface proteins on a cell and the percentage of activated cells of a cell pool is measured highly sensitively via the binding of a fluorescence-labelled monoclonal antibody to the surface protein and subsequent analysis by fluorescence-activated flow cytometry.

[0055] The reference substances employed here were both purified natural Phl p 5a (nPhl p 5a) and also rPhl p5a wt in parallel with the test substances.

[0056] The test results of the double deletion mutant Phl p 5a DM .DELTA.94-113, 175-198 with basophils from six test persons are shown as curves in FIG. 9. The test results with basophils from a total of 10 clinically defined allergy sufferers are shown in Table 2.

[0057] The A50 values (A50: allergen concentration at 50% of the number of basophils activated to the maximum) of the reference molecules were, varying individually, between .about.1.3-15 pM for rPhl p 5a wt and .about.0,3-10 pM for nPhl p 5a (Table 2). By contrast, the A50 values of deletion variant Phl p 5a DM .DELTA.94 113, 175-198 were between .about.18-8400 pM.

[0058] The A50 values determined for the three substances employed were used to determine the allergenic efficacy of deletion variant Phl p 5a DM A94-113, 175-198 in relation to the unchanged reference molecules nPhl p 5a and rPhl p5a wt for each test person (Table 2).

[0059] The relative allergenic efficacy (Pr, relative potency) of deletion variant Phl p 5a DM .DELTA.94-113, 175-198 was reduced between .about.12-5000 fold compared with the reference rPhl p 53 wt or .about.16-32000 fold compared with the reference nPhl p 5a (Table 2).

TABLE-US-00002 TABLE 2 Determination of the hypoallergeneity of deletion mutant Phl p 5a DM-.DELTA.94-113, 175-198 by means of basophil activation test Pr value .sup.b Pr value .sup.b Phl p 5a Phl p 5a DM-.DELTA.94- DM-.DELTA.94- 113, 113, 175- Test substance A.sub.50 [pM] .sup.a 175-198 198 nPhl rPhl Phl p 5a relative to relative to p p 5a DM-.DELTA.94- rPhl p 5a nPhl p Donor .sup.c 5a wt 113, 175-198 wt .sup.d 5a .sup.e P13 4.08 5.34 477.2 0.0111 0.0085 P17 6.44 2.68 466.6 0.0057 0.0137 P20 0.26 1.68 8433.0 0.0002 .sup.f 0.00003 .sup.f P23 1.02 1.26 39.2 0.0321 0.0260 P24 1.22 2.57 58.1 0.0442 0.0209 P28 9.43 11.35 198.2 0.0573 0.0476 P29 1.77 2.34 33.7 0.0694 0.0525 P31 10.15 14.66 3967.0 0.0037 0.0026 P34 3.48 2.54 165.1 0.0153 0.0211 P40 1.08 1.45 17.5 0.0829 0.0617 .sup.a Allergen concentration at 50% of the number of basophils activated to the maximum .sup.b Relative potency .sup.c Clinically defined grass pollen allergy suffers .sup.d Calculated from A50 rPhl p 5a wt /A50 Phl p 5a DM-.DELTA.94-113, 175-198 .sup.e Calculated from A50 nPhl p 5a/ A50 Phl p 5a DM-.DELTA.94-113, 175-198 .sup.f Bold: minimum and maximum values

T-Cell Reactivity

[0060] T helper lymphocytes react with peptide fragments of the allergens (approx. 12-25 amino acids) formed by enzymatic degradation in antigen-presenting cells (APCs) and are presented to the T-cells after inclusion of the suitable peptides in the individual MHC class II molecules at the surface of the APCs. This allergen-specific activation of the T helper lymphocytes is the prerequisite for subsequent reactions (proliferation, anergy, apoptosis) and for functional differentiation (TH1 and TH2). The influencing of allergen-specific T-lymphocytes by treatment with an allergen or an allergen variant in hyposensitisation is regarded as the key for the therapeutic efficacy.

[0061] In order to investigate T-cell reactivity, oligoclonal T-cell lines (TCLs) of Graminae pollen allergy sufferers are established by conventional methods with stimulation by nPhl p5 or rPhl p 5 molecules.

[0062] In a proliferation test, the various T-cell lines were stimulated with the reference allergens nPhl p5a and rPhl p5a wt and the double deletion mutant Phl p 5a DM .DELTA.94-113, 175-198. The proliferation rate was determined by the incorporation of [.sup.3H] thymidine by conventional methods.

TABLE-US-00003 TABLE 3 Determination of the T-cell reactivity of deletion mutant Phl p 5a DM-.DELTA.94-113, 175-198 by means of proliferation tests with Phl p 5-specific T-cell lines (TCLs) Stimulation index .sup.a Phl p 5a nPhl rPhl p DM-.DELTA.94-113, Donor .sup.b TCL p 5a 5a wt 175-198 A 3.2 9.8 4.9 4.4 B 8.2 21.0 15.5 13.3 C 11.2 5.2 4.7 7.2 C 11.3 3.3 2.9 3.5 C 11.43 3.0 3.9 2.6 D 19.1 6.5 4.7 7.5 D 19.2 9.6 3.3 2.6 E 23.22 21.8 29.0 20.8 E 23.50 7.5 8.4 6.6 F 89.23 1.8 3.5 1.8 .sup.a Calculated from [.sup.3H] measurement values. cpm measurement values of allergen-stimulated cell cultures/cpm measurement values of unstimulated cell cultures .sup.b Donor: clinically defined grass pollen allergy sufferers

[0063] The results with ten TCLs from six allergy sufferers show that these TCLs were stimulated to proliferation by Phl p 5a DM .DELTA.94-113, 175-198 in comparable strength as by the unchanged natural or recombinant wild-type allergen (Table 3).

[0064] The present invention thus relates to variants of the group 5 allergens of the Pooideae which are characterised by reduced IgE reactivity compared with the known wild-type allergens and by retained reactivity with T-lymphocytes. These group 5 allergens are preferably Phl p 5a, Poa p 5 and Lol p 5, very particularly preferably Phl p 5a.

[0065] As it has proven particularly favourable for the purposes of the invention for amino-acid sequence regions which correspond to amino-acid sequence regions 94-113 and 175-198 of Phl p 5a to be missing or removed in the group 5 allergens, this invention relates, in particular, to such allergen variants.

[0066] The first-mentioned or second-mentioned region may be missing individually, but also both said regions may be missing simultaneously, with the latter embodiment being very particularly preferred.

[0067] Owing to the high sequence homologies within the group 5 allergens from Pooideae, these regions can be unambiguously identified in sequence alignments of the Phl p 5a sequence with sequences from other group 5 allergens. The above-described allergen variants preferably originate from Phl p 5a or correspond to the sequences in accordance with SEQ ID NO 4, 6 or 8,

[0068] The allergen variants according to the invention can be prepared starting from the cloned DNA sequence with the aid of genetic engineering methods. In principle, however, chemical modifications of the native allergen extract are also possible (Fiebig, 1995, Allergo J. 4 (7), 377-382).

[0069] Naturally, further modifications in other positions--for example in order to increase the hypoallergeneity--are also possible via the variations of group 5 allergens described in the present patent application. These modifications can be, for example, amino acid insertions, deletions and exchanges, cleavage of the protein into fragments and fusion of the protein or fragments thereof with other proteins or peptides.

[0070] During preparation of the allergen variants described in more detail here, an His tag was introduced by genetic engineering methods for the purposes of improved purification of the overexpressed proteins.

[0071] The invention furthermore relates to a DNA molecule encoding for an allergen variant described above, in particular corresponding to a sequence in accordance with SEQ ID NO 3, 5 or 7, to a recombinant expression vector containing this DNA molecule, and to a host organism transformed with said DNA molecule or said expression vector, Suitable host organisms may be prokaryotic or eukaryotic, single- or multicelled organisms, such as bacteria or yeasts. A host organism which is preferred in accordance with the invention is E. coli.

[0072] The invention furthermore relates to a process for the preparation of an allergen variant according to the invention by cultivation of the said host organism and isolation of the corresponding allergen variant from the culture.

[0073] The present invention additionally relates to the allergen variants, DNA molecules and expression vectors described above in theft property as medicaments.

[0074] The present invention furthermore relates to pharmaceutical compositions comprising at least one of these allergen variants or a corresponding DNA molecule or a corresponding expression vector and optionally further active ingredients and/or adjuvants for the treatment of allergies in the triggering of which group 5 allergens of the Pooideae are involved, or for the immuno-therapeutic vaccination of patients having allergies in the triggering of which group 5 allergens of the Pooideae are involved and/or for the prevention of such allergies.

[0075] If these are pharmaceutical compositions of the second type (comprising at least one DNA molecule or an expression vector), these compositions preferably furthermore comprise aluminium hydroxide, an immunostimulatory CpG-containing oligonucleotide or a combination of the two as adjuvants.

[0076] For the purposes of this invention, pharmaceutical compositions can be used as therapeutic agents in human or veterinary medicine. Suitable excipients are organic or inorganic substances which are suitable for parenteral administration and do not react with group 5 allergen variants according to the invention. Suitable for parenteral administration are, in particular, solutions, preferably oily or aqueous solutions, furthermore suspensions, emulsions or implants. The allergen variants according to the invention may also be lyophilised and the resultant lyophilisates used, for example, for the preparation of injection preparations. The compositions indicated may be sterilised and/or comprise adjuvants, such as lubricants, preservatives, stabilisers and/or wetting agents, emulsifiers, salts for modifying the osmotic pressure, buffer substances and/or a plurality of further active ingredients.

[0077] Furthermore, appropriate formulation of the allergen variants according to the invention enables depot preparations to be obtained, for example by adsorption on aluminium hydroxide.

[0078] Finally, the present invention relates to the use of at least one allergen variant according to the invention or a DNA molecule according to the invention or an expression vector according to the invention for the preparation of a medicament for the treatment of allergies in the triggering of which group 5 allergens of the Pooideae are involved or for the immunotherapeutic vaccination of patients having allergies in the triggering of which group 5 allergens of the Pooideae are involved and/or for the prevention of such allergies.

Sequence CWU 1

1

221855DNAPhleum pratense 1gccgatctag gctacggccc ggccacccca gctgccccgg ccgccggcta cacccccgcc 60gccccggccg gagcggagcc agcaggtaag gcgacgaccg aggagcagaa gctgatcgag 120aagatcaacg ccggcttcaa ggcggccttg gccgctgccg ccggcgtccc gccagcggac 180aagtacagga cgttcgtcgc aaccttcggc gcggcctcca acaaggcctt cgcggagggc 240ctctcgggcg agcccaaggg cgccgccgaa tccagctcca aggccgcgct cacctccaag 300ctcgacgccg cctacaagct cgcctacaag acagccgagg gcgcgacgcc tgaggccaag 360tacgacgcct acgtcgccac cctaagcgag gcgctccgca tcatcgccgg caccctcgag 420gtccacgccg tcaagcccgc ggccgaggag gtcaaggtta tccctgccgg cgagctgcag 480gtcatcgaga aggtcgacgc cgccttcaag gtcgctgcca ccgccgccaa cgccgcgccc 540gccaacgaca agttcaccgt cttcgaggcc gccttcaaca acgccatcaa ggcgagcacg 600ggcggcgcct acgagagcta caagttcatc cccgccctgg aggccgccgt caagcaggcc 660tacgccgcca ccgtcgccac cgcgccggag gtcaagtaca ccgtctttga gaccgcgctg 720aaaaaggcca tcaccgccat gtccgaggcc cagaaggctg ccaagcccgc tgccgctgcc 780accgccaccg caacctccgc cgttggcgcg gccaccggcg ccgccaccgc cgctactggt 840ggctacaaag tctga 8552284PRTPhleum pratense 2Ala Asp Leu Gly Tyr Gly Pro Ala Thr Pro Ala Ala Pro Ala Ala Gly 1 5 10 15 Tyr Thr Pro Ala Ala Pro Ala Gly Ala Glu Pro Ala Gly Lys Ala Thr 20 25 30 Thr Glu Glu Gln Lys Leu Ile Glu Lys Ile Asn Ala Gly Phe Lys Ala 35 40 45 Ala Leu Ala Ala Ala Ala Gly Val Pro Pro Ala Asp Lys Tyr Arg Thr 50 55 60 Phe Val Ala Thr Phe Gly Ala Ala Ser Asn Lys Ala Phe Ala Glu Gly 65 70 75 80Leu Ser Gly Glu Pro Lys Gly Ala Ala Glu Ser Ser Ser Lys Ala Ala 85 90 95 Leu Thr Ser Lys Leu Asp Ala Ala Tyr Lys Leu Ala Tyr Lys Thr Ala 100 105 110 Glu Gly Ala Thr Pro Glu Ala Lys Tyr Asp Ala Tyr Val Ala Thr Leu 115 120 125 Ser Glu Ala Leu Arg Ile Ile Ala Gly Thr Leu Glu Val His Ala Val 130 135 140 Lys Pro Ala Ala Glu Glu Val Lys Val Ile Pro Ala Gly Glu Leu Gln 145 150 155 160Val Ile Glu Lys Val Asp Ala Ala Phe Lys Val Ala Ala Thr Ala Ala 165 170 175 Asn Ala Ala Pro Ala Asn Asp Lys Phe Thr Val Phe Glu Ala Ala Phe 180 185 190 Asn Asn Ala Ile Lys Ala Ser Thr Gly Gly Ala Tyr Glu Ser Tyr Lys 195 200 205 Phe Ile Pro Ala Leu Glu Ala Ala Val Lys Gln Ala Tyr Ala Ala Thr 210 215 220 Val Ala Thr Ala Pro Glu Val Lys Tyr Thr Val Phe Glu Thr Ala Leu 225 230 235 240Lys Lys Ala Ile Thr Ala Met Ser Glu Ala Gln Lys Ala Ala Lys Pro 245 250 255 Ala Ala Ala Ala Thr Ala Thr Ala Thr Ser Ala Val Gly Ala Ala Thr 260 265 270 Gly Ala Ala Thr Ala Ala Thr Gly Gly Tyr Lys Val 275 280 3795DNAPhleum pratense 3gccgatctag gctacggccc ggccacccca gctgccccgg ccgccggcta cacccccgcc 60gccccggccg gagcggagcc agcaggtaag gcgacgaccg aggagcagaa gctgatcgag 120aagatcaacg ccggcttcaa ggcggccttg gccgctgccg ccggcgtccc gccagcggac 180aagtacagga cgttcgtcgc aaccttcggc gcggcctcca acaaggcctt cgcggagggc 240ctctcgggcg agcccaaggg cgccgccgaa tccagctccg gcgcgacgcc tgaggccaag 300tacgacgcct acgtcgccac cctaagcgag gcgctccgca tcatcgccgg caccctcgag 360gtccacgccg tcaagcccgc ggccgaggag gtcaaggtta tccctgccgg cgagctgcag 420gtcatcgaga aggtcgacgc cgccttcaag gtcgctgcca ccgccgccaa cgccgcgccc 480gccaacgaca agttcaccgt cttcgaggcc gccttcaaca acgccatcaa ggcgagcacg 540ggcggcgcct acgagagcta caagttcatc cccgccctgg aggccgccgt caagcaggcc 600tacgccgcca ccgtcgccac cgcgccggag gtcaagtaca ccgtctttga gaccgcgctg 660aaaaaggcca tcaccgccat gtccgaggcc cagaaggctg ccaagcccgc tgccgctgcc 720accgccaccg caacctccgc cgttggcgcg gccaccggcg ccgccaccgc cgctactggt 780ggctacaaag tctga 7954264PRTPhleum pratense 4Ala Asp Leu Gly Tyr Gly Pro Ala Thr Pro Ala Ala Pro Ala Ala Gly 1 5 10 15 Tyr Thr Pro Ala Ala Pro Ala Gly Ala Glu Pro Ala Gly Lys Ala Thr 20 25 30 Thr Glu Glu Gln Lys Leu Ile Glu Lys Ile Asn Ala Gly Phe Lys Ala 35 40 45 Ala Leu Ala Ala Ala Ala Gly Val Pro Pro Ala Asp Lys Tyr Arg Thr 50 55 60 Phe Val Ala Thr Phe Gly Ala Ala Ser Asn Lys Ala Phe Ala Glu Gly 65 70 75 80Leu Ser Gly Glu Pro Lys Gly Ala Ala Glu Ser Ser Ser Gly Ala Thr 85 90 95 Pro Glu Ala Lys Tyr Asp Ala Tyr Val Ala Thr Leu Ser Glu Ala Leu 100 105 110 Arg Ile Ile Ala Gly Thr Leu Glu Val His Ala Val Lys Pro Ala Ala 115 120 125 Glu Glu Val Lys Val Ile Pro Ala Gly Glu Leu Gln Val Ile Glu Lys 130 135 140 Val Asp Ala Ala Phe Lys Val Ala Ala Thr Ala Ala Asn Ala Ala Pro 145 150 155 160Ala Asn Asp Lys Phe Thr Val Phe Glu Ala Ala Phe Asn Asn Ala Ile 165 170 175 Lys Ala Ser Thr Gly Gly Ala Tyr Glu Ser Tyr Lys Phe Ile Pro Ala 180 185 190 Leu Glu Ala Ala Val Lys Gln Ala Tyr Ala Ala Thr Val Ala Thr Ala 195 200 205 Pro Glu Val Lys Tyr Thr Val Phe Glu Thr Ala Leu Lys Lys Ala Ile 210 215 220 Thr Ala Met Ser Glu Ala Gln Lys Ala Ala Lys Pro Ala Ala Ala Ala 225 230 235 240Thr Ala Thr Ala Thr Ser Ala Val Gly Ala Ala Thr Gly Ala Ala Thr 245 250 255 Ala Ala Thr Gly Gly Tyr Lys Val 260 5783DNAPhleum pratense 5gccgatctag gctacggccc ggccacccca gctgccccgg ccgccggcta cacccccgcc 60gccccggccg gagcggagcc agcaggtaag gcgacgaccg aggagcagaa gctgatcgag 120aagatcaacg ccggcttcaa ggcggccttg gccgctgccg ccggcgtccc gccagcggac 180aagtacagga cgttcgtcgc aaccttcggc gcggcctcca acaaggcctt cgcggagggc 240ctctcgggcg agcccaaggg cgccgccgaa tccagctcca aggccgcgct cacctccaag 300ctcgacgccg cctacaagct cgcctacaag acagccgagg gcgcgacgcc tgaggccaag 360tacgacgcct acgtcgccac cctaagcgag gcgctccgca tcatcgccgg caccctcgag 420gtccacgccg tcaagcccgc ggccgaggag gtcaaggtta tccctgccgg cgagctgcag 480gtcatcgaga aggtcgacgc cgccttcaag gtcgctgcca ccagcacggg cggcgcctac 540gagagctaca agttcatccc cgccctggag gccgccgtca agcaggccta cgccgccacc 600gtcgccaccg cgccggaggt caagtacacc gtctttgaga ccgcgctgaa aaaggccatc 660accgccatgt ccgaggccca gaaggctgcc aagcccgctg ccgctgccac cgccaccgca 720acctccgccg ttggcgcggc caccggcgcc gccaccgccg ctactggtgg ctacaaagtc 780tga 7836260PRTPhleum pratense 6Ala Asp Leu Gly Tyr Gly Pro Ala Thr Pro Ala Ala Pro Ala Ala Gly 1 5 10 15 Tyr Thr Pro Ala Ala Pro Ala Gly Ala Glu Pro Ala Gly Lys Ala Thr 20 25 30 Thr Glu Glu Gln Lys Leu Ile Glu Lys Ile Asn Ala Gly Phe Lys Ala 35 40 45 Ala Leu Ala Ala Ala Ala Gly Val Pro Pro Ala Asp Lys Tyr Arg Thr 50 55 60 Phe Val Ala Thr Phe Gly Ala Ala Ser Asn Lys Ala Phe Ala Glu Gly 65 70 75 80Leu Ser Gly Glu Pro Lys Gly Ala Ala Glu Ser Ser Ser Lys Ala Ala 85 90 95 Leu Thr Ser Lys Leu Asp Ala Ala Tyr Lys Leu Ala Tyr Lys Thr Ala 100 105 110 Glu Gly Ala Thr Pro Glu Ala Lys Tyr Asp Ala Tyr Val Ala Thr Leu 115 120 125 Ser Glu Ala Leu Arg Ile Ile Ala Gly Thr Leu Glu Val His Ala Val 130 135 140 Lys Pro Ala Ala Glu Glu Val Lys Val Ile Pro Ala Gly Glu Leu Gln 145 150 155 160Val Ile Glu Lys Val Asp Ala Ala Phe Lys Val Ala Ala Thr Ser Thr 165 170 175 Gly Gly Ala Tyr Glu Ser Tyr Lys Phe Ile Pro Ala Leu Glu Ala Ala 180 185 190 Val Lys Gln Ala Tyr Ala Ala Thr Val Ala Thr Ala Pro Glu Val Lys 195 200 205 Tyr Thr Val Phe Glu Thr Ala Leu Lys Lys Ala Ile Thr Ala Met Ser 210 215 220 Glu Ala Gln Lys Ala Ala Lys Pro Ala Ala Ala Ala Thr Ala Thr Ala 225 230 235 240Thr Ser Ala Val Gly Ala Ala Thr Gly Ala Ala Thr Ala Ala Thr Gly 245 250 255 Gly Tyr Lys Val 2607723DNAPhleum pratense 7gccgatctag gctacggccc ggccacccca gctgccccgg ccgccggcta cacccccgcc 60gccccggccg gagcggagcc agcaggtaag gcgacgaccg aggagcagaa gctgatcgag 120aagatcaacg ccggcttcaa ggcggccttg gccgctgccg ccggcgtccc gccagcggac 180aagtacagga cgttcgtcgc aaccttcggc gcggcctcca acaaggcctt cgcggagggc 240ctctcgggcg agcccaaggg cgccgccgaa tccagctccg gcgcgacgcc tgaggccaag 300tacgacgcct acgtcgccac cctaagcgag gcgctccgca tcatcgccgg caccctcgag 360gtccacgccg tcaagcccgc ggccgaggag gtcaaggtta tccctgccgg cgagctgcag 420gtcatcgaga aggtcgacgc cgccttcaag gtcgctgcca ccagcacggg cggcgcctac 480gagagctaca agttcatccc cgccctggag gccgccgtca agcaggccta cgccgccacc 540gtcgccaccg cgccggaggt caagtacacc gtctttgaga ccgcgctgaa aaaggccatc 600accgccatgt ccgaggccca gaaggctgcc aagcccgctg ccgctgccac cgccaccgca 660acctccgccg ttggcgcggc caccggcgcc gccaccgccg ctactggtgg ctacaaagtc 720tga 7238240PRTPhleum pratense 8Ala Asp Leu Gly Tyr Gly Pro Ala Thr Pro Ala Ala Pro Ala Ala Gly 1 5 10 15 Tyr Thr Pro Ala Ala Pro Ala Gly Ala Glu Pro Ala Gly Lys Ala Thr 20 25 30 Thr Glu Glu Gln Lys Leu Ile Glu Lys Ile Asn Ala Gly Phe Lys Ala 35 40 45 Ala Leu Ala Ala Ala Ala Gly Val Pro Pro Ala Asp Lys Tyr Arg Thr 50 55 60 Phe Val Ala Thr Phe Gly Ala Ala Ser Asn Lys Ala Phe Ala Glu Gly 65 70 75 80Leu Ser Gly Glu Pro Lys Gly Ala Ala Glu Ser Ser Ser Gly Ala Thr 85 90 95 Pro Glu Ala Lys Tyr Asp Ala Tyr Val Ala Thr Leu Ser Glu Ala Leu 100 105 110 Arg Ile Ile Ala Gly Thr Leu Glu Val His Ala Val Lys Pro Ala Ala 115 120 125 Glu Glu Val Lys Val Ile Pro Ala Gly Glu Leu Gln Val Ile Glu Lys 130 135 140 Val Asp Ala Ala Phe Lys Val Ala Ala Thr Ser Thr Gly Gly Ala Tyr 145 150 155 160Glu Ser Tyr Lys Phe Ile Pro Ala Leu Glu Ala Ala Val Lys Gln Ala 165 170 175 Tyr Ala Ala Thr Val Ala Thr Ala Pro Glu Val Lys Tyr Thr Val Phe 180 185 190 Glu Thr Ala Leu Lys Lys Ala Ile Thr Ala Met Ser Glu Ala Gln Lys 195 200 205 Ala Ala Lys Pro Ala Ala Ala Ala Thr Ala Thr Ala Thr Ser Ala Val 210 215 220 Gly Ala Ala Thr Gly Ala Ala Thr Ala Ala Thr Gly Gly Tyr Lys Val 225 230 235 240924DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 9gccgatctag gctacggccc ggcc 241036DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 10aacataacta gtggcagcga ccttgaaggc ggcgtc 361130DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 11atctaactag tacgggcggc gcctacgaga 301233DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 12aacataaagc tttcagactt tgtagccacc agt 331327DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 13ggagctggat tcggcggcgc ccttggg 271445DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 14gccgccgaat ccagctccgg cgcgacgcct gaggccaagt acgac 4515375DNAPoa pratensis 15gccgccgtag acagctccaa ggccgcgctc acctccaagc tcgacgccgc ctacaagctc 60gcctacaagt cagccgaggg cgcgacgccc gaggctaagt acgacgacta cgtcgccacc 120cttagcgagg ccctccgcat cattgccggc accctcgagg tccacggcgt caagcccgcg 180gccgaggagg tcaaggccac ccccgccggc gagctccagg tcatcgacaa ggtcgacgcc 240gccttcaagg tcgctgccac cgccgccaac gccgcccccg ccaacgacaa gttcaccgtc 300ttcgaggccg ccttcaacga tgccatcaag gcgagcacgg gcggcgccta ccagagctac 360aagttcatcc ccgcc 37516382DNALolium perenne 16ggctacgccg atcaaagcaa gaaccagctc acctccaagc tcgacgccgc cttaaagcct 60cgcttacgag gctgcccagg gcgccactcc cgaggccaag tacgatgcct acgtcgccac 120cctcaccgag gcgctccgcg tcatcgccgg caccctcgag gtccacgccg taaagcccgc 180cgccgaggag gtcaaggtcg gcgccatccc cgccgccgag gtgcagctca tcgacaaggt 240cgacgccgcg tacaggaccg ccgccactgc cgccaacgcc gcccccgcca acgacaagtt 300caccgtcttc gagaacacct ttaacaatgc catcaaggtg agcctgggcg ccgcctacga 360cagctacaag ttcatcccca cc 38217378DNAHordeum vulgare 17gatcgccggc cagtccagct ccatggccaa actctccagc agcctcgaac tctcctacaa 60gctcgcctac gacaaagccc agggcgccac cccgaggcca agtacgacgc ctacgtcgcc 120accctcaccg agtcgctccg cgtcatctcc ggcaccctcg aggtccactc cgtcaagccc 180gccgccgagg aggttaaggg cgtccccgcc ggcgagctga aggccattga ccaggtcgac 240gccgccttca ggaccgccgc caccgccgct gacgctgccc cggccaacga caagttcacc 300gtcttcgagt cgcttcaaca aggtccatca aggaaaccac ggggcggcgc gtacgagagt 360tacaagttca tccccgcc 37818379DNATriticum aestivum 18gatgcccgcc cagtcagcct ccatggcatc actctccaag agcctcgaag cctcctacaa 60gctcgcctac gacaaagccc agggcgccac ccccgagacc aagtacgaca cctacgtcgc 120cagtctcacc gagtcgctcc gcgtcatctc cggcgccttc gaggtccact ccgtcaagcc 180cgccgccgag gaggtcaagg ggatccccgc cccccagctc aagaccatcg accagatcga 240cgccgcctac aggaccgccg ccaccgccgc cgacgctgcc ccggtcaacg acaagttcac 300cgtcttcgag tccgccttca acaaggccat caaggagacc acgggcggcg catacgacaa 360ctacaagttc gtccccgcc 37919206PRTPoa pratensis 19Pro Ala Ala Asn Lys Tyr Lys Thr Phe Val Ala Thr Phe Gly Ala Ala 1 5 10 15 Ser Asn Lys Ala Phe Ala Glu Ala Leu Ser Thr Glu Pro Lys Gly Ala 20 25 30 Ala Val Asp Ser Ser Lys Ala Ala Leu Thr Ser Lys Leu Asp Ala Ala 35 40 45 Tyr Lys Leu Ala Tyr Lys Ser Ala Glu Gly Ala Thr Pro Glu Ala Lys 50 55 60 Tyr Asp Asp Tyr Val Ala Thr Leu Ser Glu Ala Leu Arg Ile Ile Ala 65 70 75 80Gly Thr Leu Glu Val His Gly Val Lys Pro Ala Ala Glu Glu Val Lys 85 90 95 Ala Thr Pro Ala Gly Glu Leu Gln Val Ile Asp Lys Val Asp Ala Ala 100 105 110 Phe Lys Val Ala Ala Thr Ala Ala Asn Ala Ala Pro Ala Asn Asp Lys 115 120 125 Phe Thr Val Phe Glu Ala Ala Phe Asn Asp Ala Ile Lys Ala Ser Thr 130 135 140 Gly Gly Ala Tyr Gln Ser Tyr Lys Phe Ile Pro Ala Leu Glu Ala Ala 145 150 155 160Val Lys Gln Ser Tyr Ala Ala Thr Val Ala Thr Ala Pro Ala Val Lys 165 170 175 Tyr Thr Val Phe Glu Thr Ala Leu Lys Lys Ala Ile Thr Ala Met Ser 180 185 190 Gln Ala Gln Lys Ala Ala Lys Pro Ala Ala Ala Ala Thr Gly 195 200 205 20204PRTLolium perenne 20Pro Pro Ala Asp Lys Tyr Lys Thr Phe Val Glu Thr Phe Gly Thr Ala 1 5 10 15 Thr Asn Lys Ala Phe Val Glu Gly Leu Ala Ser Gly Tyr Ala Asp Gln 20 25 30 Ser Lys Asn Gln Leu Thr Ser Lys Leu Asp Ala Ala Leu Lys Leu Ala 35 40 45 Tyr Glu Ala Ala Gln Gly Ala Thr Pro Glu Ala Lys Tyr Asp Ala Tyr 50 55 60 Val Ala Thr Leu Thr Glu Ala Leu Arg Val Ile Ala Gly Thr Leu Glu 65 70 75 80Val His Ala Val Lys Pro Ala Ala Glu Glu Val Lys Val Gly Ala Ile 85 90 95 Pro Ala Ala Glu Val Gln Leu Ile Asp

Lys Val Asp Ala Ala Tyr Arg 100 105 110 Thr Ala Ala Thr Ala Ala Asn Ala Ala Pro Ala Asn Asp Lys Phe Thr 115 120 125 Val Phe Glu Asn Thr Phe Asn Asn Ala Ile Lys Val Ser Leu Gly Ala 130 135 140 Ala Tyr Asp Ser Tyr Lys Phe Ile Pro Thr Leu Val Ala Ala Val Lys 145 150 155 160Gln Ala Tyr Ala Ala Lys Gln Ala Thr Ala Pro Glu Val Lys Tyr Thr 165 170 175 Val Ser Glu Thr Ala Leu Lys Lys Ala Val Thr Ala Met Ser Glu Ala 180 185 190 Glu Lys Glu Ala Thr Pro Ala Ala Ala Ala Thr Ala 195 200 21208PRTHordeum vulgare 21Pro Pro Ala Asp Lys Tyr Lys Thr Phe Glu Ala Thr Phe Ala Ala Ala 1 5 10 15 Ser Asn Lys Ala Phe Ala Glu Val Leu Lys Gly Ala Ala Thr Gly Gln 20 25 30 Ile Ala Gly Gln Ser Ser Ser Met Ala Lys Leu Ser Ser Ser Leu Glu 35 40 45 Leu Ser Tyr Lys Leu Ala Tyr Asp Lys Ala Gln Gly Ala Thr Pro Glu 50 55 60 Ala Lys Tyr Asp Ala Tyr Val Ala Thr Leu Thr Glu Ser Leu Arg Val 65 70 75 80Ile Ser Gly Thr Leu Glu Val His Ser Val Lys Pro Ala Ala Glu Glu 85 90 95 Val Lys Gly Val Pro Ala Gly Glu Leu Lys Ala Ile Asp Gln Val Asp 100 105 110 Ala Ala Phe Arg Thr Ala Ala Thr Ala Ala Asp Ala Ala Pro Ala Asn 115 120 125 Asp Lys Phe Thr Val Phe Glu Ser Leu Gln Gln Gly Pro Ser Arg Lys 130 135 140 Pro Arg Gly Gly Ala Tyr Glu Ser Tyr Lys Phe Ile Pro Ala Leu Glu 145 150 155 160Ala Ala Val Lys Gln Ala Tyr Ala Ala Thr Val Ala Ala Ala Pro Glu 165 170 175 Val Lys Phe Thr Val Phe Gln Thr Ala Leu Ser Lys Ala Ile Asn Ala 180 185 190 Met Thr Gln Ala Gly Lys Val Ala Lys Pro Ala Ala Ala Ala Thr Ala 195 200 205 22210PRTTriticum aestivumMOD_RES(19)Variable amino acid 22Pro Pro Ala Asp Lys Tyr Lys Thr Phe Glu Ala Thr Phe Ser Ala Ala 1 5 10 15 Ser Asn Xaa Ala Phe Ala Asp Val Leu Lys Ala Ala Ala Ser Gly Gln 20 25 30 Met Pro Ala Gln Ser Ala Ser Met Ala Ser Leu Ser Lys Ser Leu Glu 35 40 45 Ala Ser Tyr Lys Leu Ala Tyr Asp Lys Ala Gln Gly Ala Thr Pro Glu 50 55 60 Thr Lys Tyr Asp Thr Tyr Val Ala Ser Leu Thr Glu Ser Leu Arg Val 65 70 75 80Ile Ser Gly Ala Phe Glu Val His Ser Val Lys Pro Ala Ala Glu Glu 85 90 95 Val Lys Gly Xaa Xaa Ile Pro Ala Pro Gln Leu Lys Thr Ile Asp Gln 100 105 110 Ile Asp Ala Ala Tyr Arg Thr Ala Ala Thr Ala Ala Asp Ala Ala Pro 115 120 125 Val Asn Asp Lys Phe Thr Val Phe Glu Ser Ala Phe Asn Lys Ala Ile 130 135 140 Lys Glu Thr Thr Gly Gly Ala Tyr Asp Asn Tyr Lys Phe Val Pro Ala 145 150 155 160Leu Glu Ser Ala Val Lys Gln Ala Tyr Ala Ala Thr Val Ala Ser Ala 165 170 175 Pro Glu Val Lys Tyr Ala Val Phe Gln Ala Ala Leu Ser Lys Ala Ile 180 185 190 Asn Ala Met Val Glu Ala Glu Lys Asp Ala Gly Ala Ala Ala Ala Gly 195 200 205 Gly Tyr 210

Claims

1. A variant of a group 5 wild-type allergen of the Pooideae, wherein the variant has reduced IgE reactivity compared with the wild-type allergen and substantially retains reactivity with T lymphocytes.

2. The allergen variant of claim 1, selected from the group consisting of wild-type allergens Phl p 5a, Poa p 5 and Lol p 5.

3. The allergen variant of claim 1, derived from wild-type allergen Phl p 5a.

4. The allergen variant of claim 1, wherein at least one region or a combinations of regions which correspond to amino-acid sequence regions 94-113 and 175-198 of wild-type Phl p 5a are missing compared with the wild-type allergen.

5. A variant of wild-type allergen Phl p 5a, wherein at least one region or a combinations of regions selected from amino-acid sequence regions 94-113 and 175-198 of wild-type Phl p 5a are missing.

6. The variant allergen of claim 5 having an amino-acid sequence selected from the group consisting of SEQ ID NO: 4, 6 and 8.

7. The allergen variant of claim 1, which is obtained by recombinant genetic engineering methods.

8. A DNA molecule encoding for an allergen variant of claim 1.

9-12. (canceled)

13. A medicament comprising the allergen variant of claim 1.

14. A pharmaceutical composition comprising at least one allergen variant of claim 1 and a further active ingredient and/or adjuvant.

15. A method treating an allergy triggered by a group 5 allergen of Pooideae, comprising administering at least one allergen variant of claim 1.

16-20. (canceled)

21. The pharmaceutical composition of claim 14, wherein the adjuvant is aluminum hydroxide, an immunostimulatory CpG-containing oligonucleotide or a combination thereof.

22. A method for the treatment of an allergy triggered by group 5 allergens of Pooideae species, comprising administering to a subject in need thereof the pharmaceutical composition of claim 14.